4-(4-{4-[6-(3,4-dimethoxyphenyl)pyridine-2-carbonyl]piperazin-1-yl}phenyl)morpholine | 479222-71-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 4-(4-{4-[6-(3,4-dimethoxyphenyl)pyridine-2-carbonyl]piperazin-1-yl}phenyl)morpholine
• 英文别名: 4-(4-{4-[6-(3,4-Dimethoxyphenyl)pyridine-2-carbonyl]piperazin-1-yl)phenyl)morpholine；[6-(3,4-dimethoxyphenyl)pyridin-2-yl]-[4-(4-morpholin-4-ylphenyl)piperazin-1-yl]methanone
• CAS: 479222-71-4
• 化学式: C₂₈H₃₂N₄O₄
• 分子量: 488.586
• InChiKey: BPUQSKGSOVSTJD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  36
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  67.4
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  1-[6-(3,4-dimethoxyphenyl)pyridine-2-carbonyl]-4-(4-aminophenyl)piperazine 、 二氯乙醚 在 potassium carbonate 、 sodium iodide 作用下， 以 DMF (N,N-dimethyl-formamide) 为溶剂， 生成 4-(4-{4-[6-(3,4-dimethoxyphenyl)pyridine-2-carbonyl]piperazin-1-yl}phenyl)morpholine
  参考文献：
  名称：

  PHENYLPYRIDINE CARBONYL PIPERAZINE DERIVATIVE

  摘要：

  公开号：

  EP1396487B1

文献信息

• Phenlypyridine carbonyl piperazine derivative
  申请人：——

  公开号：US20040192701A1

  公开（公告）日：2004-09-30

  The present invention relates to a compound which is represented by the following general formula and has type 4 phosphodiesterase inhibitory action, and uses and an intermediate compound thereof. 1 (wherein R1, R2: hydrogen, a halogen, a lower alkyl, a lower alkoxy, or the like, R3, R4: hydrogen, a (substituted) lower alkyl, a halogen, or the like, R5: hydrogen, a lower alkyd, a lower alkoxycarbonyl, or the like, and n: 0 or 1).

  本发明涉及一种化合物，其由以下通式表示，并具有4型磷酸二酯酶抑制作用，以及其中间体化合物和用途。(其中R1、R2：氢、卤素、低碳基、低烷氧基等，R3、R4：氢、(取代)低碳基、卤素等，R5：氢、低烷基、低烷氧羰基等，n：0或1)。
• Phenylpyridinecarbonylpiperazinederivative
  申请人：Astellas Pharma Inc.

  公开号：US07196080B2

  公开（公告）日：2007-03-27

  The present invention relates to a compound which is represented by the following general formula and has type 4 phosphodiesterase inhibitory action, and uses and an intermediate compound thereof. (wherein R1, R2: hydrogen, a halogen, a lower alkyl, a lower alkoxy, or the like, R3, R4: hydrogen, a (substituted) lower alkyl, a halogen, or the like, R5: hydrogen, a lower alkyl, a lower alkoxycarbonyl, or the like, and n: 0 or 1).

  本发明涉及一种化合物，该化合物由以下通式表示，并具有4型磷酸二酯酶抑制作用，以及其中间体化合物和用途。（其中R1、R2：氢、卤素、较低的烷基、较低的烷氧基或类似物，R3、R4：氢、（取代的）较低的烷基、卤素或类似物，R5：氢、较低的烷基、较低的烷氧羰基或类似物，n：0或1）。
• REMEDY FOR CHRONIC PELVIC PAIN SYNDROME
  申请人：Astellas Pharma Inc.

  公开号：EP1685849A1

  公开（公告）日：2006-08-02

  This invention relates to an agent for preventing or treating chronic pelvic pain syndromes (chronic abacterial prostatitis, chronic pelvic pain syndrome in a narrow sense and interstitial cystitis), which comprises various phosphodiesterase 4 (PDE 4) inhibitors such as cilomilast and roflumilast as an active ingredient.

  本发明涉及一种用于预防或治疗慢性盆腔疼痛综合征（慢性细菌性前列腺炎、狭义慢性盆腔疼痛综合征和间质性膀胱炎）的制剂，其活性成分包括各种磷酸二酯酶 4（PDE 4）抑制剂，如西洛米司特和罗氟司特。
• PDE 4 INHIBITORS FOR THE TREATMENT OF INTERSTITIAL CYSTITIS
  申请人：Astellas Pharma Inc.

  公开号：EP1685849B1

  公开（公告）日：2012-01-25
• Agent for treating chronic pelvic pain syndrome
  申请人：Kobayashi Miki

  公开号：US20070167450A1

  公开（公告）日：2007-07-19

  This invention relates to an agent for preventing or treating chronic pelvic pain syndromes (chronic abacterial prostatitis, chronic pelvic pain syndrome in a narrow sense and interstitial cystitis), which comprises various phosphodiesterase 4 (PDE 4) inhibitors such as cilomilast and roflumilast as an active ingredient.